Scientific Literature

Title Source Description
Proof of Concept: Plasma Separation Cards for Collection in Resource-Limited Settings 2014 HIV DART, December 9-12, 2014, Miami, Florida. Proof of concept study describing the functionality and performance of a new plasma separation card.
Ambient Temperature Shipping and Storage for Molecular Infectious Disease Testing: ViveST® 2014 Association for Molecular Pathology, November 12-15, 2014, National Harbor, MD. This study evaluated the stability of HIV-1 plasma samples shipped and stored on ViveST®.
Nucleic Acid and Antibody Integrity in Clinical Samples on Dried Blood Stabilization Products During Ambient Temperature Shipment 2014 American Society of Tropical Medicine and Hygiene, November 2-5, 2014, New Orleans, LA. Tested down-selected products in the field by using them to ship clinical dengue-positive whole blood samples from Iquitos to Lima, Peru for analysis.
Detection of Low Level HCV RNA in Room Temperature Stored Samples Using ViveST™, a Transformational Storage and Transport Device 2014 Clinical Virology Symposium, April 27-30, 2014, Daytona Beach, FL. This study evaluates the storage of low titer HCV plasma using ViveST™ in combination with Abbott RealTime HCV assay.
ViveST™ for HBV Testing: A Transformational Ambient Storage and Transportation Device HEP DART 2013, held December 8-12, 2013 in Hawaii. This study demonstrates the utility of ViveST™ for transportation and storage of HBV infectious plasma.
Stability of IgG and Viral RNA in Dried Whole Blood in Commercially Available RNA-Stabilization Products American Society of Tropical Medicine and Hygiene, November 13-17, 2013, Washington D.C. Evaluation of four commercially available RNA-stabilization products using whole blood.
ViveST™: A Revolutionary Ambient Temperature Storage and Transportation Device for Utilization in Infectious Disease Testing Association of Molecular Pathology, November 14-16, 2013, Phoenix, AZ Evaluated the performance of ViveST™ as a storage and transport device for downstream molecular based viral load assays.
A Novel Ambient Storage and Transport Device for Utilization in Infectious Disease Testing: ViveST™ ID Week, Annual Meeting of the Infectious Disease Society of America, October 2-6, 2013, San Francisco, California Evaluated the performance of ViveST as a storage and transport device for use with viral load and drug resistance.
A Novel Ambient Storage and Transport Device for Utilization in Infectious Disease Testing: ViveST™ International Workshop on HIV and Hepatitis Virus Drug Resistance and Curative Strategies, June 4-8, 2013, Toronto, Canada Evaluated the performance of ViveST as a storage and transport device for use with viral load and drug resistance.
Real-Time Stability of Plasma Using ViveST&trade, a Revolutionary Ambient Temperature Storage and Transportation Device 29th Clinical Virology Symposium, April 28-May 1, 2013, Daytona Beach, FL Evaluated the stability of infectious plasma samples stored on ViveST™ and analyzed with the Abbott RealTime HCV and HIV-1 viral load assays.
Evaluation of ViveST™ Using the COBAS TaqMan HCV 29th Clinical Virology Symposium, April 28-May 1, 2013, Daytona Beach, FL Evaluated the performance of COBAS® TaqMan® HCV Test, v2.0 when using HCV infected samples stored and processed on ViveST™.
Cost Comparison of Shipping Frozen Plasma Versus Ambient Temperature Shipping Using ViveST™ (HIV Dart) HIV DART 2012 (Drug Development for Antiretroviral Therapies) held in San Diego, CA, December 4-7, 2012 Compares the cost of shipping frozen plasma to the cost of shipping plasma at ambient temperature using ViveST™
HCV and HIV Testing Using a Novel Dried Ambient Sample Collection and Transport Device ViveST™ (AMP) Association for Molecular Pathology (AMP) 2012 Annual Meeting held in Long Beach, CA, October 25 - 27, 2012 Assessment of the performance of ViveST, a novel dried ambient transportation matrix, to frozen plasma for use with commercially available HCV and HIV-1 viral load and genotypic assays.
Recovery of Live Virus after Storage at Ambient Temperature Using ViveST™ Barr KL, Messenger AM, Anderson BD, Friary JA , Heil GL, Reese K, and Gray GC. Recovery of Live Virus after Storage at Ambient Temperature Using ViveST™. J Clin Virology, in press October 2012. Examines the ability of ViveST™ to preserve live virus following storage at ambient temperature.
Recovery of Live Virus from ViveST™ After Storage at Ambient Temperature 2012 International Conference on Emerging Infectious Diseases (ICEID) held in Atlanta, GA, USA, March 11-14, 2012. Studies difficulty of shipping frozen samples of various virus in developing nations where there are the lack of ultralow temperature freezers.
Comparative Effectiveness of Dried Plasma HIV-1 Viral Load Testing in Brazil using ViveST for Sample Collection Journal of Clinical Virology, December 2010, p. 245-248. Assesses the reproducibility of ViveST and compares HIV viral load results from ViveST to those from frozen plasma.
Comparative Effectiveness of Dried Plasma HBV Viral Load Testing in Three Different Viral Load Commercial Platforms Using ViveST for Sample Collection Journal of Clinical Microbiology, January 2012, p. 145-147. Assesses the reproducibility of ViveST and compares HBV viral load results from ViveST to those from frozen plasma.
Dried-Plasma Transport Using a Novel Matrix Collection System for Human Immunodefiency Virus and Hepatitis C Virus Virologic Testing Journal of Clinical Microbiology, May 2009, p. 1491-1496 A comparison of ViveST (previously SampleTanker) against frozen plasma with multiple analytes for both shipping and storage.
Measurement of HCV Viral Load and Viral Genotype from Dried Blood Spots (DBS) and a Dried Ambient Transport Matrix (ViveST) using the Abbott m2000 System The International Workshop on HIV & Hepatitis Virus Drug Resistance and Curative Strategies, June 5-9, 2012, Stiges, Spain Compares the performance of ViveST, a dried transport matrix, to plasma for viral load determination with the Abbott RealTime HCV viral load assay.
Evaluation of ViveST™ for HIV/HCV using Abbott’s RealTime Assays The 28th Annual Clinical Virology Symposium, April 20-25, 2012, Daytona Beach, Florida Compares the performance of ViveST, a dried transport matrix, to frozen plasma for use with commercially available HCV and HIV-1 viral load and genotypic assays.
Use of Dried Clinical Samples for Storing and Detecting Influenza RNA. Influenza and Other Respiratory Viruses, Nov 2011, p. 413-417 A comparison of ViveST against frozen plasma storage of specimens tested for detection of influenza RNA.
Comparison of Hepatitis Quantitative and Qualitative Methods Using ViveST Sample Transportation Matrix vs Frozen Plasma 26th Clinical Virology Symposium; April 25-28, 2010; Daytona Beach, FL, USA An evaluation of ViveST for plasma samples containing three different hepatitis virus; HBV, HCV and HDV.
Cost Effectiveness of International Shipment of Dried Plasma for HIV Resistance Testing IAS 2009; July 19-22, 2009; Cape Town, South Africa Compares fresh-frozen plasma samples to ViveST for HIV genotyping. The samples are shipped internationally from Israel and the UK, and nationally from California to Georgia.
Evaluation of ViveST®for Collection, Storage and Transport of Dried Plasma From a Resource-Limited Setting (R-LS) to a Resource-Rich Setting (R-RS) for HIV-1 Genotypic Analysis 4th International Workshop on HIV Transmission-Principles of Intervention; July 17-18, 2009; Cape Town, South Africa Utilizes ViveST for transport of HIV genotypes utilizing low-tech methods.
HIV Diversity and Drug Resistance in Western Kenya From Plasma and Non-Plasma Genotyping 4th International Workshop on HIV Transmission-Principles of Intervention; July 17-18, 2009; Cape Town, South Africa Examines HIV diversity and drug resistance in western Kenya using frozen plasma and ViveST.
Use of Plasma, Dried Plasma, and Dried Blood With Automated Sample Preparation and Detection for TRUGENE® HIV-1 Integrase Genotyping Assay 7th European HIV Drug Resistance Workshop, March 25-27, 2009; Stockholm, Sweden Compares plasma, dried plasma (ViveST), and dried blood spots genotypic analysis utilizing a prototype TRUGENE CLIP module for the TRUGENE HIV-1 integrase assay.
Development of a Genotyping Assay for HIV-1 Integrase Compatible With Globally Available IVD Platforms 20th International Congress of Clinical Chemistry and Laboratory Medicine, September 28th - October 2, 2008; Fortaleza, Brazil Reviews the performance of ViveST using the new Siemens integrase sequencing assay.
Stability of HIV-1 Viral Load From Dried Plasma Using ViveST®, a Novel Dried Plasma Transportation Matrix 24th Clinical Virology Symposium; April 25-29, 2008; Daytona Beach, FL, USA Compares the precision and stability of ViveST vs. fresh-frozen plasma. Five replicates of each sample were stored at different temperatures, measured at 5 points from day 2 through day 56. Two commercial HIV-1 viral load assays used: Roche Amplicor 1.5 and Abbott M2000.
Phenotypic and Genotypic HIV-1 Drug Resistance and Tropism Testing Performed on Plasma Stored in a Dried State 11th European AIDS Conference; October 24-27, 2007; Madrid, Spain Compares ViveST to fresh frozen plasma for viral trophism, phenotypes, and genotypes.
Comparison of Whole Blood, Plasma and PBMC HIV-1 Resistance Genotyping and Matched Dried Samples Using ViveST™, a Novel Dried Transportation Matrix XIV International HIV Drug Resistance Workshop; June 7-11, 2005; Quebec City, Canada Compares fresh-frozen plasma to ViveST plasma; whole blood to ViveST-WB; and PBMC extractions.
Comparison of Hepatitis B Virus INNO-LiPA Genotyping Between Frozen Plasma and ViveST™, a Dried Transportation Matrix 21st Clinical Virology Symposium; May 8-11, 2005; Clearwater Beach, FL, USA Demonstrates the viability of ViveST for HBV utilizing two different extraction methods, then processed on LiPA strips directed at three different areas on the HBV genome. All proved successful.
Successful International Ambient Patient Plasma Transport of HIV-1 Clade A, B and C Using ViveST™, a Novel Dried Transportation Matrix 12th Conference on
Retroviruses and
Opportunistic
Infections; February
22-25, 2005; Boston,
MA, USA
ViveST specimens were prepared and compared to FFP. The comparisons were TRUGENE HIV-1 Genotyping, HIV-1 GeneTanker complete and analyzed with MuTanker software. Samples were shipped from Israel.
Comparison of Viral Load and Resistance Genotyping Between Frozen Plasma and a Novel Dried Plasma Transportation Medium (ViveST™) on Treated Patient Samples XIII International HIV Drug Resistance Workshop; June 8-12, 2004; Tenerife Sur-Costa Adeje, Canary Islands, Spain Demonstrates the viability of ViveST with multiple commercial FDA-approved HIV-1 assays. It also demonstrated excellent results with genotyping both in HIV with TREGENE and hepatitis C.
HIV-1 Load Quantitation: A 17-Year Perspective The Journal of Infectious Diseases, September 2006 Highlights some of the history, accomplishments, and impact of Tom Merigan's laboratory on the use of HIV-1 load as a marker, as well as on updating technologies for determining HIV-1 load, their performance, interpretation of the results, and their use in clinical practice.